Brief: VaccineX Reports Two Complete Responses Study Of Pepinemab In Combination With Keytruda
26/01/2022 14:06
Jan 26 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX REPORTS TWO COMPLETE RESPONSES IN FIRST THREE
PATIENTS
ENROLLED IN THE PHASE 1B/2 KEYNOTE-B84 STUDY OF PEPINEMAB IN
COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB) IN PATIENTS WITH
RECURRENT OR METASTATIC HEAD AND NECK CANCER
Source text for Eikon: ID:nGNXy2Zkd
Further company coverage: VCNX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease